Evidence map›Paper›PMID 21883634›Full record

GuidelineThe Journal of eukaryotic microbiology

Guidelines for the naming of genes, gene products, and mutants in the opportunistic protists.

Andrew H Limper, Louis M Weiss

Abstract readGuideline
In one paragraph

Guideline in The Journal of eukaryotic microbiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Andrew H LimperThoracic Diseases Research Unit, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA. limper.andrew@mayo.edu
Louis M Weiss
Albert Einstein College of Medicine · USMayo Clinic · US

Funding

Pneumocystis: Macrophage & Epithelial ActivationR01HL062150 · NHLBI · MAYO CLINIC ROCHESTER · PI ANDREW H LIMPER · 1998 to 2026
$9.2M
New Opportunistic Infections in AIDS MicrosporidosisR01AI031788 · NIAID · YESHIVA UNIVERSITY · PI WEISS, LOUIS M. · 1992 to 2011
$4.6M
Toxoplasma encephalitis in AIDS:Bradyzoite RegulationsR01AI039454 · NIAID · YESHIVA UNIVERSITY · PI WEISS, LOUIS M. · 1996 to 2009
$3.1M
Toxoplasma gondii: cyst wallR01AI095094 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI WEISS, LOUIS M. · 2012 to 2016
$2.1M
NHLBI NIH HHS R01 HL062150NIAID NIH HHS R01 AI031788NIAID NIH HHS R01 AI039454NIAID NIH HHS R01 AI095094
6 · The paper itself

Abstract

The opportunistic protists encompass a wide diversity of organisms including Pneumocystis, Toxoplasma, cryptosporidia, microsporidia, and related genera. Recent advances in the molecular biology and cellular biochemistry of these organisms have led to the identification of an ever growing numbers of key genes and their cognate proteins. Until now, these molecules have not been designated using any consistent nomenclature system, leading to considerable confusion. The participants of the 11th International Workshop on Opportunistic Protists met on August 3, 2010 to reach consensus of a nomenclature system for genes, gene products, and mutants in the opportunistic protists. The following summary reports the consensus agreement to move toward a unified nomenclature system for these organisms. The system is adapted from that used for Saccharomyces cerevisiae.

Indexed as

Eukaryotic CellsTerminology as TopicGenetics, Microbial

Identifiers

PMID21883634
PMCPMC3703751
OpenAlexW2156773580

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.